课题基金 / 基金详情

Task V30: GMP Manufacturing of WNV Vaccine

Task V30: GMP Manufacturing of WNV Vaccine
任务 V30:西尼罗河病毒疫苗的 GMP 生产
批准号:
10794913
负责人:
WANG HONG
金额:
$143.08万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
未结题
起止时间:
2018-05-15 至 2028-05-14

项目摘要

项目成果

WANG HONG的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The Manufacture and Characterization Services (MCS) for Vaccines and Other Biologics for Infectious Diseases contract provides a variety of product development services spanning product development planning and feasibility assessments; product development and cGMP compliant manufacture for Phase I/II clinical studies; toxicology studies; technical and facility audits; and regulatory support appropriate for submission to the U.S. Food and Drug Administration (FDA). These services will facilitate the development and introduction of new vaccines and biologics against potential agents of bioterrorism and emerging and re-emerging infectious diseases. This contract also provides for manufacture of challenge material.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Task V30: GMP Manufacturing of WNV Vaccine
海外基金